The global transformation of oncology from a disease-centered discipline to molecularly informed, patient-specific care relies on genomics, bioinformatics, AI, and translational medicine. However, precision oncology’s benefits have been distributed unequally; Arab and Middle Eastern populations remain severely underrepresented in global genomic datasets, limiting the characterization of population-specific genetic variations, cancer susceptibility, and therapeutic responses.
Over the past decade, Qatar has built an interconnected ecosystem addressing this disparity. By linking population genomics, biobanking, biomedical research, clinical care, computational science, and national policy, Qatar has established a continuum from population-level discovery to clinical implementation. Initiatives like the Qatar Genome Programme (QGP) and Qatar Biobank — supported by the Qatar Biomedical Research Institute (QBRI), Sidra Medicine, and Hamad Medical Corporation (HMC) — lead this effort.
Population genomics: Establishing a foundation
Without datasets representing target populations, variant interpretation and risk prediction models (mostly derived from European cohorts) remain uncertain. QGP has substantially closed this gap. A landmark Lancet Oncology study analysed high-coverage whole-genome sequencing data from 6,142 native Qataris across six distinct ancestry groups.
The study revealed notable heterogeneity in polygenic risk scores and cancer-associated variants across ancestries. Clinically actionable, pathogenic variants in cancer susceptibility genes were identified in 1.2% of participants, with distinct distributions of BRCA1 and BRCA2 variants. These findings confirm that genomic risk cannot be uniformly extrapolated across populations, emphasising the need for population-specific validation.
From genomic discovery to translational oncology
Translating genomics into clinical tools requires connecting genomic observations with functional biology. QBRI integrates genomics, bioinformatics, and disease modeling to uncover tumor mechanisms, biomarkers, and therapeutic targets. This multi-omics approach — combining genomic, transcriptomic, proteomic, and metabolic data — provides a comprehensive view of tumor behavior and therapeutic resistance.
Sidra Medicine: Clinical Translation and Multi-Omics
Sidra Medicine serves as a pivotal bridge between research and clinical care. Its pediatric oncology program utilises a biorepository combining tumor samples, clinical data, and molecular profiles to identify actionable mutations.
In 2024, Sidra implemented clinical-grade whole-genome sequencing within Qatar, eliminating the need to send patient samples abroad. Sidra’s broader strategy integrates multi-omics analysis, machine learning, and advanced cell and gene therapies to move precision oncology directly into clinical practice.
Artificial intelligence and policy integration
Managing complex multi-omics and genomic datasets necessitates computational power. AI and machine learning are deployed across Qatari institutions to identify biomarker patterns, model disease risks, and analyse multi-omics data. However, AI predictions require rigorous clinical validation and prospective evaluation before routine clinical adoption.
Uniquely, Qatar integrates these technologies at a national policy level. The Qatar Cancer Plan 2023–2026 unifies the Ministry of Public Health, HMC, Sidra Medicine, and academic partners under a single framework for prevention, research, and care. Additionally, the Qatar Cancer Information Centre acts as a national repository, facilitating data-driven decision-making and infrastructure management.
Challenges and the road ahead
Moving beyond diagnostics, Qatar is expanding into precision therapeutics, including targeted cellular and gene-editing therapies. Sidra’s 2025 Precision Medicine Summit highlighted this exact shift toward real-world implementation.
Challenges persist. Rare genetic variants require ongoing data generation, polygenic risk scores need continuous refinement, and strict ethical frameworks must safeguard sensitive biological data. Ultimately, technological innovations are only valuable if they yield measurable improvements in patient survival and quality of life.
Qatar has developed a distinct model connecting population genomics, translational research, and national healthcare infrastructure. By addressing the lack of Middle Eastern representation in global datasets, Qatar provides critical insights into cancer biology while setting a standard for how a national health system can convert genomic knowledge into actionable clinical benefits.
- The writer is a biology educator and science writer with an MSc in Zoology, focusing on cancer biology, targeted therapeutics, and contemporary healthcare developments.